Inovio Pharmaceuticals Inc (INO)

[growsBCN]

Why Inovio Could Double In Price In Just Days

Thirdly Invovio (Nasdaq:INO)
Back in July, INO stock was super hot, it traded above $33 a share. Inovio had tested INO-4800 on non-human primates, and the results were highly promising.

The research study found that “The reduced viral loads following exposure to SARS-CoV-2 infection at this timeframe demonstrate an important durable impact mediated by INO-4800.”

This was not only encouraging, but perhaps historic. As Inovio reported, this trial marked “the first time a vaccine protection in non-human primates was reported from memory immune responses as previously reported monkey vaccine challenge studies were conducted at the time near their peak immune responses…”

On top of that, in August, Inovio reported that all participants in a 38-person trial demonstrated overall immune responses. Plus, there were no reported serious adverse events. Overall, both the company and its investors were in celebration mode.

Inovio stock sold off after the U.S. Food and Drug Administration notified Inovio that it “has additional questions about the company’s planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800,” as reported by Inovio.

Market participants reacted harshly, slamming the INO share price. Risk-tolerant traders should consider the possibility that this was an overreaction.

Just because the Phase 2/3 trial has been put on pause, doesn’t mean that it is tabled permanently. The FDA is giving Inovio a chance to respond to its questions. And if all goes well, the trial could still be in progress in November.

Much of this piece on Inovio is credited to talented writer Louis Navellier from InvestorPlace Research.

Once FDA clears Inovio this stock could double over night. I believe buying now in the $10 range is a bet worth taking.

https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5514870-why-workhorse-virgin-galactic-inovio-double-in-price-in-just-days